Cargando…

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States

Background and Aims: The current paradigm of specialist physician-managed treatment of chronic hepatitis C virus infection (HCV) is inefficient in absorbing the approximately 3 million patients awaiting treatment in the United States. Task shifting—whereby specialist physicians screen patients for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jayasekera, Channa R., Beckerman, Rachel, Smith, Nathaniel, Perumpail, Ryan B., Wong, Robert J., Younossi, Zobair M., Ahmed, Aijaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411351/ https://www.ncbi.nlm.nih.gov/pubmed/28507921 http://dx.doi.org/10.14218/JCTH.2016.00052

Ejemplares similares

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Trends in Liver Transplantation in Hepatitis C Virus–Infected Persons, United States
por: Perumpail, Ryan B., et al.
Publicado: (2016)

An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma
por: Wong, Robert J., et al.
Publicado: (2022)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience
por: Aggarwal, Avin, et al.
Publicado: (2017)

Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States
por: Siddique, Osama, et al.
Publicado: (2017)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher
por: Perumpail, Ryan B., et al.
Publicado: (2016)

Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care
por: Younossi, Zobair M., et al.
Publicado: (2016)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States
por: Stepanova, Maria, et al.
Publicado: (2017)

It is time to expand the fatty liver disease community of practice
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
por: Zhang, Sai, et al.
Publicado: (2015)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
por: Cox‐North, Paula, et al.
Publicado: (2017)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
por: Boyer, Sylvie, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
por: Leleu, H, et al.
Publicado: (2015)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
por: Esteban, Rafael, et al.
Publicado: (2022)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Younossi, Zobair M., et al.
Publicado: (2021)

The importance of a multidisciplinary approach to hepatocellular carcinoma
por: Siddique, Osama, et al.
Publicado: (2017)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i5053ngkp9u1291rg2i0moeujn